An Open, Non-controlled, Parallel, Ascending Multiple-dose, Multicenter Study to Assess Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of SOBI003 in Pediatric MPS IIIA Patients
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 08 Feb 2018
At a glance
- Drugs SOBI 003 (Primary)
- Indications Mucopolysaccharidosis III
- Focus Adverse reactions
- Sponsors Swedish Orphan Biovitrum
- 02 Feb 2018 Status changed from planning to not yet recruiting.
- 23 Jan 2018 According to a Swedish Orphan Biovitrum media release, the FDA has issued a Study may proceed letter for this trial and accepted the investigational new drug (IND) application.
- 24 Oct 2016 New trial record